Li Peng

机构：Hebei Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Fourth Hospital of Hebei Medical University · ORCID：0000-0003-2030-1807

发表论文 14 篇 · 总被引 168 次 · h-index 8

代表论文

• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 51)
• Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation (2020 · Scientific Reports · 被引 22)
• Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases (2021 · Pathology & Oncology Research · 被引 21)
• Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age (2020 · Breast Cancer Research and Treatment · 被引 15)
• Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer (2021 · Breast Cancer Research and Treatment · 被引 12)
• Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer (2020 · Medicine · 被引 12)